Viewing Study NCT05559359


Ignite Creation Date: 2025-12-24 @ 2:44 PM
Ignite Modification Date: 2026-02-21 @ 4:08 AM
Study NCT ID: NCT05559359
Status: RECRUITING
Last Update Posted: 2025-12-09
First Post: 2022-09-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module